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Abstract
Background: In resource-limited settings where HIV-1 is endemic, there is a need for simple, inexpensive but
effective rapid methods for detecting recent infections and estimating incidence for the purposes of surveillance
and management. We sort to determine possible reasons for reported misclassifications of recent HIV-1
seroconversion as determined with the S/LS assay in sub-Saharan Africa.
Findings: We used the modified Determine HIV-1/2 sensitive/less sensitive method for determining recent HIV-1
seroconversion to determine recent infections among ELISA repeat HIV-1 positive samples from blood donors.
Furthermore, HIV-1 seropositivity was confirmed using a line immunoassay and the results used to validate the
performance of the modified Determine HIV-1/2 S/LS assay. The results confirmed reported misclassifications of
recent HIV-1 seroconversion in sub-Saharan Africa. It was noted that, lack of confirmation of HIV-1 seropositivity in
suspected cases of HIV-1 contributed to misclassifications.
Conclusions: It was concluded that, with confirmation of HIV-1 seropositivity, the modified Determine HIV-1/2 S/LS
assay will be a rapid and cost effective method for determining HIV-1 recent infections and estimating incidence in
resource-limited settings. The need for detailed studies to validate simple methods for determining recent HIV-1
infections is emphasized.
Findings
In resource-limited settings where HIV-1 is a burden,
the need for reliable incidence surveillance data to help
access performance of interventions as well as monitor
transmission patterns cannot be overestimated. It is
however unfortunate that such settings are coupled with
challenges such as equipment and technical expertise.
Standard assays, like the 3A11-LS for determining
recent HIV infections may be impossible to use in these
settings which therefore calls for alternative reliable but
cheaper methods to determine recent HIV-1 serocon-
version and estimate incidence. Improved laboratory
methods for determining recent human immunodefi-
ciency virus type 1 (HIV-1) seroconversion and estimat-
ing incidence have been widely reported [1-9].
Improvements in these methods help eliminate the use
of longitudinal studies, back calculations and other
cohort studies which are not only costly but also require
consistent follow up of clients and repeated testing
which is problematic and much difficult to perform in
resource-poor settings [10]. Methods for determining
recent HIV-1 infections in single serum samples include
minipool (MP) nucleic acid amplification testing (NAT)
and individual donation (ID) NAT, detection of p24
antigen and the sensitive/less sensitive (S/LS) method
for detecting recent HIV-1 seroconversion [3]. NATs
and p24 antigen testing are costly and require specific
laboratory equipments to perform. A report on the cost-
effectiveness of including MP or ID NAT and or p24
antigen testing to blood screening in Ghana found that
it was highly costly to perform such tests [11]. The sen-
sitive/less sensitive strategy however seems simpler and
‘less costly’ to be used in resource-limited settings.
Detection of recent seroconversion can provide informa-
tion on serologically undetected residual infections,
monitor transmission trends in a community and also
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have been performed in some African countries using
the S/LS EIA to determine recent HIV-1 seroconversion
and estimate incidence [12-15]. It has however been
reported that some of these assays give misleading
results when used in Sub-Saharan Africa [16].
Recent HIV-1 seroconversion was determined among
76 blood donor plasma samples which tested repeatedly
double reactive on the Genescreen Ultra HIV Ag-Ab
ELISA which was used at the time of the study for rou-
tine HIV screening at the National Public Health &
Reference Laboratory, Accra, Ghana. Of the 76 ELISA
repeat reactive samples, 41 tested repeatedly reactive on
the Determine™ HIV-1/2 (Abbott Laboratories, Abbott
Park, IL) rapid test. These plasma samples (n = 41) were
subsequently taken through the modified Determine S/
LS (Det-S/LS) protocol as described elsewhere [8]. The
protocol classified 23 as recent seroconversions and the
remaining 18 as longstanding seroconversions. Due to
previous reports of misclassifications, we further per-
formed the INNO-LIA™ confirmatory assay to ascertain
the HIV-1 antibody seropositivity on all the initial 76
ELISA double repeat reactive samples. After confirma-
tion, only one of the 23 recent seroconversion samples
turned out to be seropositive for HIV-1. It was thus
c o n c l u d e dt h a to n l yt h i sw a sat r u er e c e n tH I V - 1s e r o -
conversion. All the 35 negative samples as determined
by the Determine™ HIV-1/2 rapid test initially were
also negative by INNO-LIA™. All the longstanding ser-
oconversions as determined by the modified Det-S/LS
protocol were confirmed as seropositive for HIV-1. On
the INNO-LIA™ strip, the one recent seroconversion
showed intense (3+) bands for antibodies to five HIV-1
proteins (sgp120, gp41, p31, p24, & p17).
For blood donor screening, the use of a very sensitive
assay is recommended. These assays though having high
sensitivities are not very specific as observed in this
study. In the absence of PCR, INNO-LIA™ is a good
alternative gold method for confirming HIV-1 and HIV-
2 seropositivity. This is employed in many resource-lim-
ited settings where PCR is not available. In this study,
the existing systems were used to troubleshoot a local
problem. It was observed that, screening samples with
the Det-S/LS assay without confirmation was likely to
result in an overestimation of recent HIV seroconver-
sion. Any calculations therefore using the misclassified
recent data would result in overestimation of incidence
of HIV-1 infection. Though fourteen (14) of the initial
recent seroconversions were indeterminate on INNO-
LIA™, the classification algorithm for recent infections
by INNO-LIA as reported by Schupbach and his collea-
gues [17] could not be used due to absence of clinical
information on the blood donor samples used. This
classification however is questionable by our results as
recent HIV seroconversion did not correspond to faint
banding patterns on INNO-LIA™ as reported. We will
therefore like to stress that, incidence estimates calcu-
lated with recent seroconversion data obtained using S/
LS and other antibody based recent seroconversion algo-
rithms are likely to be overestimated if HIV seropositiv-
ity is not confirmed.
Our results also indicate that, the modified rapid tests
may be a good alternative for determining recent HIV-1
seroconversion and estimating incidence in resource-
limited settings. There is therefore a need extensive
work into this area of research. Since INNO-LIA™ is
used as a confirmatory test for HIV in Ghana and other
settings, there is a need for further studies to character-
ize seroconversion status of individuals whose antibody
status are indeterminate on INNO-LIA™ and clearly
define an algorithm for classifying recent seroconversion
a ss u g g e s t e d[ 1 7 ] .B yt h i ss t u d yw ep r o p o s eas i m p l e
cost-effective algorithm for determining recent HIV-1
seroconversion in resource limited settings (figure 1).
The likely positive samples are taken through the Det-S/
LS protocol as described by Soroka et al [8]. Suspected
recent seroconversions are subsequently confirmed for
their HIV-1 seropositivity using INNO-LIA™.T h e
number of tests for INNO-LIA™ at this stage thus will
be reduced as compared to performing INNO-LIA™
from step 1. In bigger systematic studies, persons classi-
fied by this algorithm as false recent seroconvertions
m a yb ef o l l o w e du po raP C Rp e r f o r m e dw h e r et h e
facility exists to ascertain whether they are really nega-
tive for HIV-1 or not.
Figure 1 Algorithm for determining recent HIV-1
seroconversion using the modified Determine sensitive/less
sensitive protocol.
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